"The global Lasik market continues to grow, and the Technolas Teneo laser, which has a compact footprint, has been well received and widely adopted in more than 50 countries. Our plan to initiate a series of clinical trials, and ultimately pursue regulatory approval for this technology in the United States, is part of our commitment providing surgeons with a full suite of innovations to meet the needs of their patients."

-Chuck Hess, vice president and general manager, U.S. Surgical, Bausch + Lomb, in a news release this week in which B+L announced it plans to begin a series of U.S. clinical trials designed to evaluate the safety and efficacy of Technolas Teneo excimer laser for vision correction surgery for myopia and myopic astigmatism. The trials are expected to begin by July.